At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Potential treatments identified that may offer improved outcomes in COVID-19 patients with increased thrombus formation
Alameda, Calif. -- Fluxion Biosciences announced two recent publications on COVID-19 and its ability to lead to high levels of platelet coagulation and an increased risk of thrombosis. The first study, published by a team at the University of Pennsylvania School of Medicine, was published in May 2021 as a preprint in bioRxiv, and is titled “Signaling through FcgRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19”. The second publication, published by a team at the University Hospital of Tuebingen in Blood Advances on January 10, 2022, is titled “Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19”.
Although predominantly a respiratory disease, COVID-19 has been shown to cause a range of responses, including adverse effects on the cardiovascular system. Some patients have an inflammatory response that may trigger thrombosis, and there is a high incidence for those with severe illness.
In the first paper, researchers at the University of Pennsylvania identified key mediators of inflammation and cardiovascular disease in COVID-19 patients that correlated positively with platelet activation in the BioFlux system. The Syk inhibitor fostamatinib reversed platelet hyperactivity in BioFlux experiments. The researchers concluded that this represents a distinct, targetable signaling pathway to modulate this effect.
The second paper, by researchers at the University of Tuebingen, demonstrated that reduced cAMP (cyclic adenosine monophosphate) levels in platelets increased antibody-induced platelet coagulation and thrombus formation. These effects were inhibited by iloprost, a clinically-approved therapeutic agent that increases intracellular cAMP levels in platelets.
Both papers relied on the BioFlux system to assess platelet function in COVID-19 patients. The BioFlux system acts as an “artery on a chip” that precisely controls the cell micro-environment and provides real-time, high resolution images of thrombus formation. Used in more than 500 labs globally, the BioFlux system is available in a variety of configurations to meet the application requirements of any laboratory. Systems are available with a range of capabilities and throughputs for applications in basic research, drug discovery, and diagnostic development.
About Fluxion Biosciences Fluxion’s pioneering cell analysis technologies are used globally by laboratories to research novel biology, accelerate drug discovery, and tailor therapies based on patient-specific biomarkers. For more information about Fluxion’s pioneering technologies, visit https://fluxionbio.com.